Related Experiment Videos
Noxa in colorectal cancer: a study on DNA, mRNA and protein expression
Agneta K Jansson1, Anna M Emterling, Gunnar Arbman
1Division of Oncology, Department of Biomedicine and Surgery, Linköping University, S-581 85 Linköping, Sweden. agnja@ibk.liu.se
Abstract:
Noxa is a BH3-only member of the Bcl-2 family, upregulated by p53 as a response to DNA damage. Mutations in the BH3-only region of other BH3-only members lead to an inactive protein. We have investigated the mRNA expression of Noxa with real-time PCR in 94 unselected colorectal adenocarcinomas and the corresponding normal mucosa. Among them, Noxa protein expression was investigated with immunohistochemistry in 16 tumors and six corresponding normal mucosa samples. Further, we searched for Noxa mutations in all the cases using single-stranded conformation polymorphism and DNA sequencing. The mRNA expression of Noxa was weak in 9% and strong in 2% of the tumors, and decreased in 9% and increased in 16% of the tumors compared with the normal mucosa; however, these changes did not have any clinical or pathological significance. The protein level in most of the cases investigated was correlated with the mRNA level. We did not find any mutations in the Noxa gene. Thus, we suggest that Noxa may not be of importance in the development of colorectal cancer.
Insights
Noxa, a p53-regulated gene, showed no significant mutations or expression changes in colorectal cancers. These findings suggest Noxa (a BH3-only protein) may not play a key role in colorectal cancer development.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Noxa is a BH3-only protein in the Bcl-2 family, induced by p53 in response to DNA damage.
- Mutations in other BH3-only proteins can inactivate them, impacting apoptosis.
- The role of Noxa in colorectal cancer development is not well understood.
Purpose of the Study:
- To investigate the mRNA and protein expression of Noxa in colorectal adenocarcinomas.
- To identify mutations in the Noxa gene in colorectal cancer patients.
- To determine the potential significance of Noxa in colorectal cancer development.
Main Methods:
- Real-time PCR was used to analyze Noxa mRNA expression in 94 tumor and normal mucosa samples.
- Immunohistochemistry was employed to assess Noxa protein levels in 16 tumor and 6 normal mucosa samples.
- Single-stranded conformation polymorphism and DNA sequencing were performed to detect Noxa gene mutations.
Main Results:
- Noxa mRNA expression showed minor variations in tumors compared to normal mucosa, lacking clinical or pathological significance.
- Noxa protein levels generally correlated with mRNA levels across the studied samples.
- No mutations were detected in the Noxa gene in any of the investigated colorectal cancer cases.
Conclusions:
- The study found no significant alterations in Noxa gene mutations or expression in the analyzed colorectal adenocarcinomas.
- These findings suggest that Noxa may not be a critical factor in the pathogenesis of colorectal cancer.
- Further research may be needed to fully elucidate the role of Noxa in other cancer types or contexts.